Difference between revisions of "Figitumumab (CP-751,871)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the NCI Drug Dictionary: A human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antine...") |
m |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
From the NCI Drug Dictionary: A human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab selectively binds to IGF1R, preventing insulin-like growth factor type 1 (IGF1) from binding to the receptor and subsequent receptor autophosphorylation. Inhibition of IGF1R autophosphorylation may result in a reduction in receptor expression on tumor cells that express IGF1R, a reduction in the anti-apoptotic effect of IGF, and inhibition of tumor growth. | From the NCI Drug Dictionary: A human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab selectively binds to IGF1R, preventing insulin-like growth factor type 1 (IGF1) from binding to the receptor and subsequent receptor autophosphorylation. Inhibition of IGF1R autophosphorylation may result in a reduction in receptor expression on tumor cells that express IGF1R, a reduction in the anti-apoptotic effect of IGF, and inhibition of tumor growth. | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' CP-751,871 | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| − | [[Category:Anti- | + | [[Category:Intravenous medications]] |
| − | [[Category: | + | [[Category:Anti-IGF-1R antibodies]] |
| + | [[Category:Halted drugs]] | ||
[[Category:Stub]] | [[Category:Stub]] | ||
Latest revision as of 02:01, 26 July 2023
Mechanism of action
From the NCI Drug Dictionary: A human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab selectively binds to IGF1R, preventing insulin-like growth factor type 1 (IGF1) from binding to the receptor and subsequent receptor autophosphorylation. Inhibition of IGF1R autophosphorylation may result in a reduction in receptor expression on tumor cells that express IGF1R, a reduction in the anti-apoptotic effect of IGF, and inhibition of tumor growth.
Also known as
- Code name: CP-751,871